A brief project overview is enough for the initial conversation. Confidential data can be shared securely after the call and, if required, under an NDA.
Not sure whether your data are ready?
Your team tests the prioritized candidates using the most appropriate experimental assay.
We compare the results with the computational ranking, explain agreements and discrepancies, and refine the next round when follow-up analysis is included in the project scope.
You receive a clear ranked table, mutation-level rationale, interface maps, confidence notes, and a focused shortlist. The result answers a practical question: which candidates deserve expression, measurement, and comparison in the next wet-lab cycle?
5. Receive a decision-ready shortlist
We compare candidates using the agreed structural and interaction workflow. Each variant is evaluated consistently for predicted effects on the binding interface, molecular contacts, and relevant risk factors, with clear confidence notes included alongside the ranking.
4.Analyze and rank candidates
Before calculation, we review chain identities, sequence and structure coverage, missing residues, interface definition, ligand or cofactor states, and relevant assay context. We document assumptions and flag limitations.
3. Confirm data readiness
Provide what you already have:
PDB or mmCIF structures, FASTA sequences, mutation or candidate lists, antigen information, and optional assay data.
If a reliable 3D structure is unavailable, sequence-led modeling can be added to the project.
2. Share your available data
Tell us what your team needs to decide: which antibody variants to express, test, or advance. We translate this into a focused comparison plan and agree on the scope, timeline, required inputs, and success criteria before the analysis begins.
- Define the research question
One decision at a time.
A narrow scientific question creates a report that is easier to validate and easier to use.